Cediranib
Anaplastic Astrocytoma
National Cancer Institute (NCI)Small moleculePhase 2Active
BBB
73/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 95/ 100
Competitive context
34 Active assets in the Anaplastic Astrocytoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan City of Hope Medical Center | Phase 2/3 | BBB |
(+)-Vincristine Novartis Pharmaceuticals | Phase 2/3 | BB |
Carboplatin Oliver Jonas | Phase 2 | BB |
Cintredekin Besudotox INSYS Therapeutics Inc | Phase 1/2 | BB |
Trametinib National Cancer Institute (NCI) | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →